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D4.1
Treatment of Critical Limb Ischemia
Overall Strategy for Treatment of Critical Limb Ischemia
Many of the principals of basic treatment discussed in relation to patients with intermittent clau-
dication also apply to patients with CLI, although the urgency for rapid treatment of the latter
group will alter the emphasis. For instance , the management of risk factors such as hyperlipi -
demia is not of any immediate importance in patients with CLI. By contrast, other important
aspects in the immediate basic treatment of patients with CLI, such as adequate control of pain,
do not apply to claudication.
The principal urgent components of basic treatment of CLI are the control ofpain and any
infection in the ischemic leg, prevention of progression of thrombosis if this is thought to be a
precipitating factor in the ischemia, and the optimization of cardiac and respiratory function .
While instituting basic treatment, the full precise morphology of the PAD should be simultane-
ously established by some form of imaging technique. This will determine further management
of the arterial lesion. In a small group of patients, often delayed referrals, ischemia and gross
infection in the leg pose an immediate threat to the patient's survival. An immediate major
amputation is mandatory and can be life saving in these cases, for instance , in a patient with gas
or septic gangrene .
In most patients, the various options for endovascular techniques, arterial surgery, or thromboly-
sis can be carefullyweighed. The primary aim is revascularization to provide sufficient blood flow
to relieve the rest pain and heal skin lesions. Most patients with CLI have multisegment arterial
disease, and often the elimination of the most proximal obstruction might be sufficient to achieve
these aims. It is, however, important to resist the temptation to only treat a relatively easy proxi-
mal lesion in the presence of extensive distal disease where the marginal improvement in blood
flow may be insufficient to achieve healing. This applies especiallywhere there has been tissue
loss. For instance, angioplasty for relatively minor iliac stenosis is unlikely to achieve healing of a
foot ulcer in the presence of extensive infrainguinal disease (see also D 4.2.2, P 5194).
In general, if there is a balanced choice between an endovascular and a surgical procedure for a
particular lesion, then the former is preferred because it usually avoids a general anesthesia,
poses a lesser systemic stress, and has fewer serious complications. However, the choice between
an endovascular and a surgical procedure depends largely on the exact level and extent of the
arterial disease; hence the need for a collaborative discussion of each case between endovascular
and surgical specialists. For the same reason, in this section the optimal technique for revascular-
ization is discussed on an anatomic basis.
Having identified the best interventional techniques in a particular case, the risks and chances of
success have to be weighed . There is no doubt that in some cases in which the risks of revascu-
larization are high and the chances of success low, there is a place for a primary major amputa-
tion or noninterventional therapy. Although a nu mber of techniques are available for assessing
the risks and benefit of a particular revascularization procedure in a particular patient, they are
still far from perfect. This is reflected by the number of patients who have an attempt at a series
of revascularization procedures that fail to achieve their purpose even in the short term and cul-
minate in a major amputation.
There may be additional considerations in deciding whether to advise a patient to have a prim-
ary amputation. Not infrequently, patients with CLI will have other serious conditions limiting
mobility, for instance, a neurological deficit from previous stroke. In fitter patients, it is neces-
sary to estimate the chances of a patient fully mobilizing on an artificial limb. There may be an
argument for primary amputation in a patient who is likely to mobilize well on a prosthesis and
in whom the chances of a successful revascularization are slight.
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More recently, available treatment options have been extended by the possibility of pharma-
cotherapy as a principal treatment. Published evidence so far only relates to the use of pharm a-
cotherapy in patients with CLI who were unsuitable for any form of revascularization or in
whom attempts at revascularization have already failed. In these selected patients, pharma-
cotherapy may help to avoid or delay a major amputation and should be considered. The possi-
bility of pharmacotherapy as a primary alternative to revascularization has not so far been stud-
ied . Its more established role is as an adjunct to either endovascular or surgical revascularization,
where there is some evidence that adjunctive pharmacotherapy improves early and medium-term
results at very little risk.
In summary, the management of a patient with CLI should proceed rapidly in conjunction with
delineation of the arterial lesion. This is followed by a decision on the optimal form of revascu-
larization, which, if successful, will reverse the changes of CLI with minimum risk. If both
surgery and endovascular techniques are equally feasible and likely to succeed initially and
durably, the latter is preferred to surgery. The second decision is whether to apply this form of
revascularization or proceed to a primary amputation. Pharmacotherapy is a useful adjunct, but
its role as primary treatment is not yet established.
D 4.2 Basic Treatment for Critical Limb Ischemia
D 4.2.1 Control of Pain
A hallmark of CLI is ischemic rest pain and painful ulceration. Etiology of the pain is multifac-
torial, but it is primarily related to ischemia of the skin in the distal extremity. Pain control is a
critical aspect of the management of these patients. Ideally, relief of pain is achieved by reperfu-
sion of the extremity. However, while setting up reperfusion, adequate pain control must be a
goal of management in all patients. Furthermore, in patients for whom revascularization is not
possible, acetaminophen, nonsteroidal antiinflammatory drugs, or narcotics may be necessary.
Pain control should be individualized and multifactorial.
Physicians should assess pain severity and adequacy of pain relief in all patients at regular visits.
Several pain scales are available, but simple scales that range from 0 to 10, with "0" indicating
no pain and " 10"indicating the most severe pain , are useful. Such scales should be evaluated
and recorded in the chart at each visit. Initial attempts at pain relief should include the use of
acetaminophen or nonsteroidal antiinflammatory drugs. Caution should be used in the latter in
patients with hypertension or renal insufficiency. Patients with severe unrelenting ischemic pain
also may require narcotics for adequate pain relief. Control of pain is usually more effective if
analgesia is given regularly rather than on demand. In patients undergoing intervention, nar-
cotics also may be required during the postoperative period. Placing the affected limb in the
dependent position provides partial relief of ischemic pain in some patients. Tilting the bed or
use of a reclining chair therefore may be helpful measures in addition to analgesia.
Spinal cord stimulation has also been used in patients with inoperable severe lower extremity
ischemia (see also D 4 .16 .4, P S264). However, it currently cannot be recommended in patients
with CLI. Sec Recommendation 82 (p S194). Epidural block is another effectiveform of pain
control in various ABPI cases.
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Recommendation 82: Pain control in critical limb ischemia
Adequate treatment of ischemic pain is mandatory in all patients with eriticallimb
ischemia and may require short-term use of narcotics. Pain control should be individu-
alized and multifactorial. However, pain control treatment should not delay defmitive
treatment of the arterial lesion.
D 4.2.2 Foot Care in Patients With Critical Limb Ischemia
Patients with chronic CLI must pay particular attention to proper foot care and avoid trauma to
their extremities. These patients should be evaluated by a podiatrist and evaluated for proper foot
care. Extremes of heat and cold should be avoided. Even mild physical trauma can convert a
patient from having intact skin to an ischemic ulcer. Thus, local measures are extremely impor-
tant in the overall management of these patients (see also D 1.4, The Diabetic Foot, p 5173).
D 4.2.3 Treatment of Life-Threatening Coexisting Disease
Patients with CLI are at the highest risk for subsequent myocardial infarction, stroke, and vas-
cular death. Therefore, in addition to addressing the needs of their extremity, it is critical to
reduce the systemic risk of mortality in this patient population. Many of these patients have
impaired cardiac and renal function, sometimes having frank cardiac or renal failure. These
coexisting conditions require active treatment by an expert in these areas. Improvement of car-
diac output also will inevitably improve peripheral perfusion and go some way toward treating
the CLI.
D 4.2.4 Treatment of Ulcers and Gangrene
Topical therapy
Several attempts have been made to improve topical therapy for ischemic wounds in patients
with CLI. This includes the use of topical antibiotics, growth factors, and debriding agents.
These treatments are attractive and are often h.ighlypromoted by their sponsors. However,
there are almost no controlled randomized trials to document the benefits of any topical agent
to augment wound healing in this patient population. There may be substantial risk to the use
of this therapy, because allergic reactions leading to dermatitis can be common with topical
antibiotics'! Furthermore, reliance on topical therapy carries the risk of delaying reperfusion,
and, except in neuropathic ulcers, topical agents are unlikely to be successful as the sole therapy.
These agents are also expensive and often unnecessarily raise the expectation of the patient for a
good result despite the absence of therapeutic efficacy.
Several novel dressings also have been proposed to neat these patients. These include
hydrophilic dressings and seaweed. Most of the experience with these dressings has been in
venous ulcers and not arterial ischemic ulcers. Again, there are no data to support their use.
Local treatment should aim to save as much skin tissue as possible; debridement should be
avoided or kept at a minimum. Wet dressings, soaked in saline, can be used a few times a day to
eliminate pus and tissue debris. Moist dressings also may be useful in reducing pain. Only once
the ulcer has dried out should dry dressings be used. There is no indication for immobilizing a
patient with an ischemic ulcer, unless the ulcer is on a weight-bearing area. A review of a few
studies with becaplermin (rhPDGF-BB) gel suggests that ulcer healing may be improved.s The
effectiveness of current topical agents-antibiotics, growth factors or hormones, debriding
agents, or occlusive dressings-is not established.
Recommendation 83: Topical therapy for ischemic ulceration
Topical therapy for ischemic ulceration should be guided by the principles of wound
care. The extremities should be kept clean, with appropriate debridement.
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Systemic therapy
The use of systemic antibiotics may be indicated in patients with cellulitis. This is commonly
seen in patients with diabetes with ischemic wounds and may occur in any patient who converts
from dry to wet gangrene, or who develops an infected ulcer. Signs and symptoms include
swelling, redness, and tenderness at the site of infection. Bacteriology of these wounds is often
polymicrobial, particularly in patients with diabetes. Therefore, signs of infection need to be
aggressively treated. This often requires the use of systemic antibiotics to achieve adequate
blood levels. Additional systemic agents for treating ischemic wounds have not undergone rig-
orous trials. Anticoagulation is generally not warranted except in an attempt to maintain graft
patency (see D 4.3.3, Pharmacotherapy adler Than Prostanoids, P 5199, and D 4.13.3, Other
Drugs, p 5149). Antiplatelet therapy is useful as already described to reduce the systemic risk of
cardiovascular disease (see Recommendation 28, p 583).
Recommendation 84: Systemic antibiotic therapy in patients with critical limb ischemia
Systemic antibiotics are required in patients who develop cellulitis or spreading infec-
tion in ischemic ulcers or gangrene but should not delay more definitive treatment.
D 4.2.5 Control of Risk Factors
Patients with CLI have the same cardiovascular risk factor profile as patients with claudication.
However, patients with CLI have a more diffuse and extensive degree of atherosclerosis.
Therefore, their risk of cardiovascular events and mortality is higher than that of patients with
claudication. Despite the end-stage nature of this disease, aggressive systemic risk factor modifi-
cation is still warranted.
Smoking cessation
The progression of peripheral arterial disease from asymptomatic to claudication to ischemic rest
pain is highly associated with cigarette smoking. In patients with severe disease, graft patencies
are dearly improved by smoking cessation. This is true for both vein as well as prosthetic graft
material. Amputation rates are also highly correlated with persistent cigarette smoking. In two
series, the amputation rate was between 11% and 23% in those who continued to smoke, versus
oto 10% in those who were smoking abstinent.f Finally, patient survival at 1, 3, and 5 years is
also highly correlated with smoking. Therefore, in patients with severe end-stage disease, smok-
ing cessation is still highly beneficial (see Recommendation 22, p S80).
Hypertension
Hypertension is a risk factor for all forms of cardiovascular disease. Although blood pressure ele-
vations are a risk factor for peripheral arterial disease, maintaining an adequate blood pressure is
important for limb perfusion. In patients with claudication, aggressive treatment of hyperten-
sion is associated with a modest reduction in treadmill exercise performance. In patients with
severe chronic limb ischemia, aggressive blood pressure treatment may decrease limb perfusion
and thus result in worsening ischemic rest pain or delayed healing of ischemic ulcers.
Historically, patients with CLI have been treated by plasma volume expansion to increase blood
pressure, thereby improving distal blood flow.s This therapy may be associated with temporary
benefit but does expose the patient to the risk of stroke, congestive heart failure, and other
untoward cardiovascular events. Therefore, inducing hypertension in this patient population is
not recommended. Conversely, patients hospitalized for treatment of their severe leg ischemia
should not have their blood pressure acutely lowered unless there is evidence of active coronary
ischemia or congestive heart failure. Because there is the possibility of vasoconstriction with
beta-blocker antihypertensive agents, their use in CLI should be carefully considered. Whcn
such antihypertensives are used, CLI patients should be monitored for worsening of ischemic
ulcers.
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Diabetes
Diabetes is an important risk factor for all forms of peripheral arterial disease and also greatly
contributes to CLI (see A 2, Epidemiology, Natural History, Risk Factors, p 85). In addition to
the risk of atherosclerotic arterial occlusive disease, patients with diabetes also develop neuropa-
thy, which increases the risk for developing nonhealing neurotrophic ulcers. In addition to the
neuropathy, hyperglycemia will inhibit white cell function, thus predisposing the patient to
infection (see also D 1.4, The Diabetic Foot p 8173). A comprehensive approach to treating
patients with diabetes would include proper footwear, with attention to areas of trauma from
poorly fitting shoes (see D 4.2.2, Foot Care, p 5194). Patients with nonhealing ulcers often
need to be treated in the hospital to provide comprehensive management, including wound care
and eventually systemic antibiotics. In addition, aggressive control of blood sugar is warranted
in these patients, with an attempt to maintain fasting blood sugars below 120 rngydl, and post-
prandial sugars less than 180 mg/dL. Chronic management should attempt to normalize glyco-
hemoglobin levels to less than 7.0% (see Recommendation 23, p 580).
llyperlipide~ia
The lipid risk profile for patients with peripheral arterial disease is similar between those with
claudication and those with eLI. There are no data regarding recommendations in the severe
leg ischemia patient population. However, extrapolation from patients with intermittent claudi-
cation as well as from the National Cholesterol Education Program Guidelines would recom-
mend aggressive treatment ofLDL cholesterol levels and attempts to raise the HDL cholesterol
and lower triglyceride levels. Therefore, patients with CLI should have an LDL cholesterolleve1
maintained at 100 mg/dL or less (see Recommendation 25, p S81). The goals of therapy are
to reduce the systemic risk of myocardial infarction and cardiovascular death, as well as to delay
the progression of peripheral atherosclerosis.
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